MTS raw data values, after being blank-corrected to wells containing growth medium and DMSO only, are pasted into the pre-formatted Excel template spread sheet for further calculations. The absorbance values that are higher than average "time 0 plate" absorbance value, are calculated as % of control, vehicle-treated cells at 144h, according to the following formula: 
SEL24-B489 pharmacokinetics, metabolic stability and CYP inhibition
Pharmacokinetics properties of SEL24-B489 were analyzed in three different species. CD-1 mice (three females per timepoint) were dosed with 50 mg/kg by oral gavage (PO) and with 15 mg/kg given intravenously (IV). Three SD male rats were treated with 25 mg/kg PO or 1 mg/kg IV. Three male Beagle dogs were administered 5 mg/kg PO and 1 mg/kg IV. SEL24-B489 was freshly dissolved in water at the required concentrations. To assess pharmacokinetic properties of a compound, whole blood was collected at the selected timepoints, plasma was extracted and stored at -80 °C for further analyses. PK parameters of SEL24-B489 are given in Supplementary  Table 6 . Of note, the compound exhibited good oral bioavailability calculated as 62 % in mice, 52 % in rats and 47 % in dogs.
Stability of SEL24-B489 was tested in the Liver S9 fraction as well as in liver microsomes across all tested species -mouse, rat, dog, human. Tested compounds (at initial concentration of 1 µM) were incubated at 37 °C Supplementary Figure 1: Chemical structure of SEL24-B489. (5,6-dibromo-4-nitro-2-) piperidin-4-yl)-1-(propan-2-yl)-1H-1,3-benzimidazole). Chemical formula and molecular weight are given for free base.
with liver microsomes or the S9 fraction in the presence or absence of enzyme cofactors. The assay was performed in triplicate, at four time points (0, 20, 40 and 60 minutes) with the respective reference samples (i.e. without cofactors). After incubation, drug transformation by liver enzymes was terminated by adding cold acetonitrile. The loss of compound was determined by LC-MS analysis. Results were adjusted for reaction volume and protein concentration, and presented as intrinsic clearance. The analysis of two standard compounds (i.e. positive and negative controls) was included. In these analyses, SEL24-B489 exhibited good stability, with a half-life (T 1/2 ) varying from 2.6 hours in mice to 9.9 hours in the human S9 fraction, and 7.2 hours in mice to 21.1 hours in human microsomes. (Supplementary Table 7) . SEL24-B489 CYP-inhibitory activity was measured at Cambridge Bioscience Limited (except CYP1A2 inhibition which was measured in-house). The compound was tested in a 5-dose IC50 mode with 3-fold serial dilution starting at 30 μM. The control compound Ketoconazole was tested in a 10-dose IC50 with 3-fold serial dilution starting at 10 μM. SEL24-B489 showed a very weak potential for CYP inhibition with IC50 between 12.6 and 22.1 µM (Supplementary Table  8 ), indicating its low potential for causing drug-drug interaction. MOLM-13 (FLT3-ITD+), MOLM-16 (FLT3-WT) and KG-1 (FLT3-WT) cells expressing high levels of PIM kinases, were treated with SEL24-B489 for 4 hours in a dose-dependent manner and analyzed for phosphorylation of S6 kinase using flow cytometer (charts) and Western blot (photographs). A -AC220 and L -LGH-447 compounds were used as reference. C -vehicle control. Samples no 1-6 -peripheral blood; Samples no 7-19 -bone marrow; N-newly diagnosed, previously untreated; RRrelapsed or refractory, previously treated; NA -not assessed; U-unclassifiable. In vitro activity of SEL24-B489 in AML cell lines -GI50. Cell viability after 72 h incubation with serial dilutions of SEL24-B489, AZD-1208, AC220 and cytarabine, was determined using the MTS assay. GI50 (50% of growth inhibition) was determined from the sigmoidal dose-response curve (GraphPad Prism). FLT3-ITD+ cell lines: MV-4-11, MOLM-13. FLT3-WT cell lines: MOLM-14, MOLM-16, KG-1, EOL-1, KASUMI-3, KASUMI-6, OCI-AML-2, OCI-AML-3, MOLM-6, RS4;11, SKNO-1, SKM-1, SIG-M5, GDM-1, PL-21. Table 6 : Pharmacokinetic properties of SEL24-B489 in mice, rats and dogs. Pharmacokinetic profiles of SEL24-B489 in mice (CD-1), rats (Sprague Dawley) and dogs (Beagle) were determined after oral and intravenous administration. PO -per os, IV -intravenous, T 1/2 -elimination half-life, C max -peak plasma concentration, T max -time to reach C max , AUC -area under the curve, F -bioavailability. . CYP activity was assessed as described in the Supplementary methods as above.
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